Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven

Royal Brisbane and Women's Hospital, Herston

University Hospital Zurich, Zurich

Universitair Ziekenhuis Gent, Ghent

University Hospital Gent - Department of Hematology, Ghent

Rosewell Park Cancer Institute, Buffalo

Fox Chase Cancer Center, Philadelphia

Emory Clinic, Atlanta

Emory University Hospital, Atlanta

Emory University Investigational Drug Service, Atlanta

IDS Pharmacy, Birmingham

University of Alabama at Birmingham-, Birmingham

University Hospitals of Cleveland, Cleveland

UHHS - Westlake, Westlake

Cleveland Clinic, Cleveland

Gabrail Cancer Center, Dover

Gabrail Cancer Center, Canton

Universitaetsklinik Bonn, Medizinische Klinik und Poliklinik III, Bonn

Universitaetsmedizin der Johannes Gutenberg-Universitaet, III. medizinische klinik und Poliklinik, Mainz

Northwestern Medical Faculty Foundation, Chicago

CH Lyon Sud, Pierre-Bénite

Hôpital Saint-Louis, Paris

Hôpital André MIGNOT, Le Chesnay

Nevada Cancer Institute-, Las Vegas

University of California Medical Center, San Francisco

California Cancer Care, San Mateo

California Cancer Care, Inc., Greenbrae

University of Alabama at Birmingham-, Birmingham

The University of Texas M.D. Anderson Cancer Center, Houston

Prince Of Wales Hospital, Shatin N.T.

Universita La Sapienza Cattedra di Ematologia, Roma

Erasmus Medisch Centrum--, Rotterdam

Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw

Asan Medical Center, Seoul

Hospital Clinic I Provincial de Barcelona, Barcelona

Derriford Hospital - Plymouth, Plymouth

Somers Cancer Science Building MP824, Southampton

Bart's Cancer Institute; Queen Mary University of London, London